OncoMatch/Clinical Trials/NCT06222879
Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer
Is NCT06222879 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including HRS-8080; SHR-A1811 and HRS-8080; SHR-A2009 for breast cancer.
Treatment: HRS-8080; SHR-A1811 · HRS-8080; SHR-A2009 · SHR-A2009; SHR-1316 — This study is designed to determine if treatments with the combination of HRS-8080 and SHR-A1811, the combination of HRS-8080 and SHR-A2009, the combination of SHR-A2009 and SHR-1316 are safe, tolerable, and has anti-cancer activity in patients with unresectable or metastatic breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Allowed: ESR1 positive
ER positive
Allowed: HER2 (ERBB2) positive
HER2 positive
Allowed: HER2 (ERBB2) negative
HER2 negative
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
Good functional level of the organs
Kidney function
Good functional level of the organs
Liver function
Good functional level of the organs
Good functional level of the organs
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify